This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.2 (urea cycle disorders) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | Urea cycle disorders (UCD), hyperammonemia, CPS1 deficiency (carbamoyl phosphate synthetase 1 deficiency), OTC deficiency (ornithine transcarbamylase deficiency), NAGS deficiency (N-acetylglutamate synthase deficiency), urea cycle enzyme deficiency |
| C. Adult onset | Possibility of first diagnosis in adulthood: present (especially OTC deficiency) — In female heterozygous carriers of OTC deficiency, cases first diagnosed in adulthood with acute hyperammonemic encephalopathy after a high-protein diet, surgery, infection, or childbirth have been reported; mild-type CPS1 deficiency can also manifest in adulthood; OTC deficiency is sometimes discovered late after liver transplantation. |
| 1. History | 1932 discovery of the urea cycle by Krebs and Henseleit → 1962 first description of OTC deficiency (Russell) → 1964 report of CPS1 deficiency → 1984 cloning of the OTC gene → 1990s establishment of emergency treatment protocols for hyperammonemia → 2000s clinical introduction of nitrogen scavengers (benzoate/phenylbutyrate). |
| 2. Causes | Deficiency of 6 enzymes or 2 transporters in the urea cycle. CPS1 (mitochondrial, autosomal recessive), NAGS (mitochondrial, autosomal recessive), OTC (mitochondrial, X-linked), citrullinemia (ASS1), argininosuccinic aciduria (ASL), argininemia (ARG1), ORNT1/SLC25A15 (HHH syndrome), SLC25A13 (CITRIN). |
| 3. Genetics | OTC gene (Xp11.4): X-linked recessive. CPS1 (2q35), NAGS (17q21): autosomal recessive. OTC deficiency is severe in males; female carriers range from asymptomatic to severe. NAGS deficiency, a deficiency of the activator (N-acetylglutamate), responds to carglumic acid treatment. |
| 4. General epidemiology | About 1 in 35,000 for all UCD combined (by newborns). OTC deficiency accounts for about 50-60% of all UCD. Based on registration at the Korean rare disease information center, OTC deficiency is the most frequently reported. Occurs in all ethnic groups. |
| 5. Pathophysiology | Blockade of the urea cycle → ammonia accumulation → cerebral edema, astrocyte swelling, glutamine overaccumulation → brainstem compression and brain herniation. Secondary accumulation of precursor metabolites (carbamoyl phosphate, ornithine, citrulline, etc.) according to the site of blockade at each step of urea synthesis in hepatic mitochondria. |
| 6. Symptoms | Severe neonatal form: feeding refusal, vomiting, lethargy, seizures, and coma (hyperammonemic encephalopathy) within 24-72 hours of birth. Chronic/mild form: anorexia, protein aversion, failure to thrive, cognitive decline, recurrent vomiting. Female OTC carriers: acute encephalopathy postpartum or after high-protein intake. |
| 7. Signs | Markedly elevated blood ammonia (> 100-150 μmol/L). Hyperventilation (Kussmaul breathing). Plasma amino acids: elevated glutamine, decreased arginine, enzyme-specific metabolite patterns. Urine orotic acid: elevated in OTC, ASS1, and ASL deficiency; normal to decreased in CPS1 and NAGS deficiency. |
| 8. Screening | Newborn tandem MS/MS: citrulline (elevated in ASS1 and ASL deficiency), arginine (elevated in ARG1 deficiency). OTC, CPS1, and NAGS deficiency can be missed on newborn screening, so immediate measurement of blood ammonia is essential when clinically suspected. |
| 9. Diagnosis | Blood ammonia measurement, plasma amino acid chromatography, urine organic acids (orotic acid), liver or red blood cell enzyme activity, gene panel (OTC, CPS1, NAGS, etc.). Female carriers of OTC deficiency: allopurinol loading test to confirm excessive orotic acid excretion. |
| 10. Treatment | Acute hyperammonemia: discontinuation of protein intake (48 hours), high-calorie intravenous glucose and lipid supply, nitrogen scavengers (intravenous sodium benzoate and sodium phenylacetate), hemodialysis (in severe cases). Chronic: low-protein diet, arginine/citrulline supplementation, phenylbutyrate (glycerol phenylbutyrate, GPB). NAGS deficiency: carglumic acid. Liver transplantation is curative treatment. |
| 11. Prognosis | Mortality is high in the untreated severe neonatal form. Persistent hyperammonemic encephalopathy causes neurodevelopmental impairment (decreased IQ, cerebral palsy). Ammonia normalizes after liver transplantation. Long-term maintenance of a low-protein diet and metabolic control are key to preserving cognitive function. The mild form in female OTC carriers has a relatively good prognosis. |
| 12. Prevention | Early diagnosis by newborn screening (tandem MS/MS). Family genetic counseling (identification of female carriers of OTC deficiency). Avoidance of factors that trigger metabolic stress, such as infection, surgery, and a high-protein diet. Application of the emergency regimen in case of fever or decreased appetite. All patients with urea cycle disorders carry a medical alert card. |
| 13. References | Häberle J et al. J Inherit Metab Dis. 2019, and 9 others |
The biochemical mechanism of urea synthesis was first systematized in 1932, when Hans Adolf Krebs and Kurt Henseleit of Germany discovered the cyclic pathway of urea synthesis (Krebs-Henseleit cycle, urea cycle). This discovery, which revealed the key mechanism by which mammals convert ammonia into less toxic urea for renal excretion, became a milestone in the history of biochemistry, and Krebs later received the 1953 Nobel Prize in Physiology or Medicine for the discovery of the TCA cycle (citric acid cycle).
Clinical description of genetic disorders caused by urea cycle enzyme deficiencies began in earnest in the 1960s. In 1962, Russell, Leizner, and colleagues first reported ornithine transcarbamylase (OTC) deficiency with neonatal hyperammonemia, and in 1964 Freeman and colleagues described carbamoyl phosphate synthetase 1 (CPS1) deficiency. Around the same time, ASS1 deficiency (citrullinemia), ASL deficiency (argininosuccinic aciduria), and ARG1 deficiency (argininemia) were also each reported with clinical cases. As it was recognized that these diseases occur within the same metabolic pathway, the concept of 'urea cycle disorders (UCD)' was established.
In 1979, Batshaw and Brusilow developed an ammonia-lowering therapy using the nitrogen scavengers sodium benzoate and sodium phenylacetate, bringing innovation to the emergency treatment of urea cycle disorders. These drugs conjugate with glycine and glutamine and excrete nitrogen through the kidneys via a urea-independent pathway. When clinical results of combined nitrogen scavenger therapy were published in 1984, the survival rate of neonates with severe urea cycle disorders improved greatly.
The OTC gene (Xp11.4) was cloned in 1984, the CPS1 gene (2q35) in the 1990s, and the NAGS gene (17q21) in 2002. This made gene-level diagnosis and carrier testing possible. In the 2000s, glycerol phenylbutyrate (GPB) was developed, improving long-term maintenance therapy for nitrogen removal. In 2004, carglumic acid (N-carbamylglutamate) was approved in Europe as a specific treatment for NAGS deficiency, and was subsequently approved in the United States and Korea as well. Liver transplantation began to be performed as a curative option for urea cycle disorders in the 1980s and is now established as the standard long-term treatment for severe UCD. Recently, research on AAV vector-based hepatocyte gene therapy and mRNA therapeutics has been actively under way.
Urea cycle disorders are caused by hereditary deficiency of enzymes or transporters in the urea synthesis pathway that proceeds in hepatic mitochondria and cytosol. The urea cycle is a five-step cyclic pathway that converts toxic ammonia (NH₃) generated during amino acid breakdown into urea for renal excretion.
The steps of the urea cycle and the associated deficiency diseases are as follows. Step 1: in mitochondria, ammonia + CO₂ + 2ATP → carbamoyl phosphate. Enzyme: CPS1 (carbamoyl phosphate synthetase 1). Activating cofactor: N-acetylglutamate (NAG), produced by the synthetase NAGS. Deficiency: CPS1 deficiency, NAGS deficiency → blockade of carbamoyl phosphate production → primary ammonia accumulation. Step 2: carbamoyl phosphate + ornithine → citrulline. Enzyme: OTC (ornithine transcarbamylase, inner mitochondrial membrane). X-linked deficiency. Step 3: citrulline + aspartic acid → argininosuccinic acid. Enzyme: ASS1 (argininosuccinate synthetase). Deficiency: citrullinemia type I. Step 4: argininosuccinic acid → arginine + fumaric acid. Enzyme: ASL (argininosuccinate lyase). Deficiency: argininosuccinic aciduria. Step 5: arginine → urea + ornithine. Enzyme: ARG1 (arginase 1). Deficiency: argininemia.
This file focuses on CPS1 deficiency, NAGS deficiency, and OTC deficiency (see separate files for ASS1, ASL, and ARG1 deficiency). CPS1 deficiency is caused by pathogenic variants in the CPS1 gene (2q35) and is inherited in an autosomal recessive manner. NAGS deficiency is caused by variants in the NAGS gene (17q21.31) and is autosomal recessive. OTC deficiency is caused by variants in the OTC gene (Xp11.4) and is X-linked. CPS1 deficiency and NAGS deficiency block the most upstream step of the urea cycle and therefore tend to cause the most severe hyperammonemia. OTC deficiency is the most common urea cycle disorder, accounting for about half of all UCD.
Besides the urea cycle itself, hyperammonemia also occurs from transporter deficiencies. SLC25A15 (ORNT1) deficiency, a deficiency of the ornithine/citrulline exchange transporter of the inner mitochondrial membrane, causes HHH syndrome (hyperornithinemia-hyperammonemia-homocitrullinuria). SLC25A13 (citrin) deficiency, a deficiency of the aspartate-glutamate transporter, causes adult-onset citrullinemia type II or neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD).
The mode of inheritance of urea cycle disorders differs depending on the causative gene. Only OTC deficiency is X-linked; all the others (CPS1, NAGS, ASS1, ASL, and ARG1 deficiency, HHH syndrome, and NICCD) are autosomal recessive.
OTC gene (Xp11.4): 9 exons, 73 kb. More than 1,000 pathogenic variants have been registered. In males (hemizygous), OTC activity is absent or markedly reduced, and they usually show severe neonatal hyperammonemia. Some mild missense variants may cause delayed symptoms or a mild presentation from childhood to adulthood. In female carriers (heterozygous), OTC expression varies from person to person owing to random inactivation (lyonization) of the normal X chromosome, so the phenotype forms a continuous spectrum from asymptomatic carriers to severe hyperammonemic encephalopathy. The proportion of de novo OTC variants is about 20-30%, so the disease can occur even without a family history.
CPS1 gene (2q35): 38 exons, about 120 kb. More than 500 pathogenic variants have been reported, and most are rare variants specific to individual families (private mutations). Complete-deficiency variants are associated with the severe neonatal form, and missense variants with residual activity with the mild form.
NAGS gene (17q21.31): 7 exons. N-acetylglutamate (NAG), produced by NAGS, is an essential activating cofactor of CPS1. In NAGS deficiency, even if CPS1 is normal, CPS1 function is lost owing to the absence of the activating cofactor. Carglumic acid is a synthetic analog of NAG that directly activates CPS1, and is therefore a specific treatment for NAGS deficiency. NAGS deficiency is very rare but clinically important because of its dramatic response to carglumic acid. In genotype-phenotype correlation, complete deficiency gives the severe neonatal form, and some missense variants give a mild to moderate phenotype.
Genetic counseling: in OTC deficiency, if the mother is a carrier, sons have a 50% risk of being affected and daughters a 50% risk of being carriers. The proportion of de novo variants is high, so the disease occurs even without a family history. In autosomal recessive diseases (CPS1, NAGS, etc.), the risk of disease in siblings is 25%. After molecular genetic confirmation, genetic testing of family members and prenatal diagnosis (CVS, amniocentesis) or preimplantation genetic testing (PGT) are possible.
The overall incidence of urea cycle disorders is estimated at about 1 in 35,000 newborns, a figure obtained by summing the frequencies of the individual diseases. Among these, OTC deficiency is the most common, accounting for about 50-60% of all UCD, followed in order by ASS1 deficiency (citrullinemia type I), ASL deficiency (argininosuccinic aciduria), CPS1 deficiency, ARG1 deficiency, and NAGS deficiency. The frequency of CPS1 deficiency is about 1 in 800,000, and NAGS deficiency is rarer, estimated at 1 in several million.
The sex distribution shows a distinctive pattern in OTC deficiency. Owing to X-linked inheritance, the severe neonatal form predominates in males, and female carriers also show diverse phenotypes from asymptomatic to acute hyperammonemic encephalopathy. In autosomal recessive diseases (CPS1 and NAGS deficiency), the disease occurs equally in both sexes. In Korea, the number of patients registered with urea cycle disorders in Health Insurance Review & Assessment Service (HIRA) and rare disease registry data is reported at the level of several dozen per year, with OTC deficiency accounting for the largest proportion. In tandem mass spectrometry-based newborn screening, OTC deficiency and CPS1 deficiency have no specific metabolic markers and may be missed on screening, so immediate measurement of blood ammonia is essential when clinically suspected.
Mortality remains high in severe neonatal hyperammonemia. In severe neonatal OTC deficiency or CPS1 deficiency, if blood ammonia exceeds 1,000 μmol/L and coma persists, neurological damage is severe and mortality is high. Neurodevelopmental disorders (intellectual disability, seizures, cerebral palsy) are also common among survivors. Survival improves in patients who receive appropriate treatment and dietary control, but long-term cognitive outcome depends greatly on the duration and intensity of hyperammonemia. After liver transplantation, the metabolic abnormality is corrected and long-term prognosis improves greatly.
The key pathophysiology in urea cycle disorders is brain damage due to ammonia toxicity. Normally, ammonia (NH₄⁺/NH₃) generated during amino acid breakdown is converted to urea through the urea cycle in hepatic mitochondria and excreted by the kidneys. When urea cycle enzymes are deficient, this process is blocked and blood ammonia rises rapidly.
Mechanism of ammonia neurotoxicity: Ammonia freely crosses the blood-brain barrier and enters brain astrocytes. In astrocytes, glutamate is converted to glutamine through a reaction in which glutamine synthetase captures ammonia. Because glutamine is an osmotically active substance, excessive accumulation of glutamine within astrocytes causes osmotic imbalance and cell swelling (astrocyte swelling), leading to cerebral edema and raised intracranial pressure. In addition, glutamine accumulation within mitochondria induces the mitochondrial permeability transition (MPT), resulting in oxidative stress, ATP depletion, and cell death.
Ammonia directly induces neuronal dysfunction and cell death through NMDA receptor overactivation (excitotoxicity), oxidative stress (generation of reactive oxygen species), and neurotransmitter imbalance (disruption of the glutamate and GABA systems). EEG shows slow-wave activity, epileptiform waves, and burst-suppression patterns. Encephalopathy symptoms appear when blood ammonia is 100 μmol/L or higher, and at 500 μmol/L or higher the risk of coma and herniation rises sharply.
Excess accumulation of carbamoyl phosphate: When carbamoyl phosphate accumulates in mitochondria in OTC deficiency, it spills over into the cytosolic pyrimidine synthesis pathway, orotic acid is overproduced, and large amounts are excreted in urine. Elevated urine orotic acid is used as a diagnostic marker of OTC deficiency (and ASS1 and ASL deficiency). In contrast, in CPS1 and NAGS deficiency, carbamoyl phosphate itself is not produced, so orotic acid is at normal to decreased levels, which is useful for biochemical differentiation of the two groups.
Effects of chronic hyperammonemia: Even in repeated or chronic mild to moderate hyperammonemia, neurodevelopmental disorders accumulate, and intellectual disability, learning disorders, behavioral problems, and seizures can occur. Even if blood ammonia is kept close to normal through treatment, neurological damage that has already occurred is difficult to recover, which underscores the importance of early diagnosis and continuous metabolic control.
The clinical symptoms of urea cycle disorders show a wide spectrum from the severe neonatal form to mild adult-onset presentation, depending on the type of deficient enzyme, residual enzyme activity, and precipitating factors.
Severe neonatal form (complete deficiency): Characterized by onset within a few days of birth (24-72 hours of age). Findings are normal at birth, and blood ammonia rises rapidly as protein intake begins with feeding. Initial symptoms are nonspecific: feeding refusal, lethargy, vomiting, and hyperventilation (Kussmaul breathing, central hyperventilation). It progresses rapidly to seizures and coma (hyperammonemic encephalopathy), and without treatment can cause death within days. Blood ammonia commonly rises to 500-1,000 μmol/L or higher. At this stage, clinical differentiation from neonatal sepsis is very difficult, so blood ammonia must be measured whenever a newborn has lethargy or seizures.
Mild/chronic and late-onset forms: When residual enzyme activity remains, symptoms do not appear until childhood or adulthood, and acute hyperammonemia is triggered by metabolic stress (infection, surgery, delivery, excessive protein intake, fasting, fever). Chronic symptoms include anorexia, protein aversion (behavior of voluntarily avoiding high-protein foods such as meat), failure to thrive, recurrent vomiting, cognitive decline, headache, and behavioral problems. In some patients, migraine-like headache is the dominant symptom and may lead to misdiagnosis.
Characteristics of female carriers of OTC deficiency: Show diverse phenotypes from asymptomatic to intermittent headache and vomiting, and rarely acute hyperammonemic encephalopathy. Cases first diagnosed with a sudden change in consciousness after delivery or after a high-protein diet have been reported. In adult women with encephalopathy of unknown cause or symptoms resembling hepatic encephalopathy, female carriers of OTC deficiency must be differentiated.
Specificity of NAGS deficiency: The symptom presentation pattern of NAGS deficiency is similar to that of CPS1 deficiency, but it has the clinical feature of a dramatic response to carglumic acid administration. In some patients, the disease does not manifest in the neonatal period and first presents in childhood or adolescence with intermittent hyperammonemia.
The main laboratory findings and physical signs of urea cycle disorders, organized by enzyme, are as follows.
Blood ammonia: The key indicator of urea cycle disorders. The diagnostic criteria for hyperammonemia are > 110 μmol/L in newborns, > 80 μmol/L in infants, and > 50 μmol/L in children and adults. In the severe neonatal form it can reach 500-2,000 μmol/L. Blood ammonia must be placed on ice, transported immediately to the laboratory, and analyzed within 30 minutes to prevent false positives (in vitro ammonia generation).
Plasma amino acid chromatography: Glutamine is markedly elevated (a common finding in urea cycle disorders), and arginine is decreased. Enzyme-specific metabolite patterns appear: decreased citrulline in OTC, CPS1, and NAGS deficiency; markedly elevated citrulline in ASS1 deficiency (citrullinemia); elevated argininosuccinic acid in ASL deficiency; elevated arginine in ARG1 deficiency. This pattern is the key clue for differentiating the enzymes.
Urine orotic acid: Markedly elevated in OTC deficiency (excess carbamoyl phosphate is diverted to the pyrimidine synthesis pathway, increasing orotic acid production). Normal or even decreased in CPS1 and NAGS deficiency, which is important for differentiating the two groups. Orotic acid may also be mildly to moderately elevated in ASS1 and ASL deficiency.
Physical signs: In acute hyperammonemic encephalopathy, decreased consciousness (lethargy → coma), respiratory abnormalities (rapid, deep breathing = hyperventilation accompanied by respiratory alkalosis), seizures, dystonia, opisthotonos, and signs of brain herniation (pupillary abnormalities, respiratory arrest) are observed. In the chronic form, neurodevelopmental abnormalities such as failure to thrive, hepatomegaly (in some patients), learning disorders, and behavioral problems are observed on physical examination. In some patients, skin spots (cutaneous vascular abnormalities) or hair abnormalities accompany the disease.
Imaging findings: Brain MRI in the acute encephalopathy phase may show restricted diffusion (DWI) in the basal ganglia (putamen, globus pallidus) and cerebral cortex, and chronic brain injury may show white matter abnormalities and cortical atrophy.
Newborn screening for urea cycle disorders is partly included in tandem mass spectrometry (MS/MS)-based expanded newborn screening. However, there is an important limitation: in OTC, CPS1, and NAGS deficiency, changes in blood amino acids are minimal in the neonatal period, so they can be missed on standard tandem MS/MS screening.
UCD detectable by tandem MS/MS: ASS1 deficiency (markedly elevated citrulline), ASL deficiency (elevated citrulline + elevated argininosuccinic acid), and ARG1 deficiency (elevated arginine) are relatively well detected on newborn screening. When citrulline is elevated, differentiation from citrullinemia type II (citrin deficiency, SLC25A13 variants) is needed, which is relatively common in East Asia, including Korea.
Screening limitations in OTC, CPS1, and NAGS deficiency: Decreased neonatal plasma citrulline has been proposed as a screening marker for these diseases, but its specificity is low. Therefore, early detection of these diseases depends on clinical suspicion rather than newborn screening. The key is to measure blood ammonia immediately when a newborn has lethargy, vomiting, or hyperventilation. If a family member has a urea cycle disorder, molecular genetic confirmatory testing in the neonatal period is performed first.
Screening of female carriers of OTC deficiency: The allopurinol loading test is used as an adjunct for identifying female carriers of OTC deficiency. If urinary excretion of orotic acid and orotidine increases abnormally after allopurinol administration, the likelihood of being a carrier is high. However, the sensitivity of this test is not 100%, so molecular genetic OTC gene testing (targeted testing after identifying the familial variant, or NGS) is the standard for confirming carrier status.
Diagnosis of urea cycle disorders proceeds from biochemical testing to molecular genetic confirmation, and in emergency situations immediate measurement of blood ammonia is the top priority.
Blood ammonia measurement: When a urea cycle disorder is suspected, blood ammonia measurement should be done first. Ammonia must be measured immediately in all newborns with lethargy, vomiting, or hyperventilation, in patients with altered consciousness of unknown cause, and in those with symptoms resembling hepatic encephalopathy. After blood collection, the sample is placed on ice immediately, transported, and analyzed within 30 minutes. Blood ammonia > 150 μmol/L requires immediate therapeutic intervention and consultation with a metabolic specialist.
Plasma amino acid chromatography: Elevated glutamine is a common finding in urea cycle disorders, and the citrulline level is the key to differentiating the deficient enzyme. Low citrulline + elevated orotic acid = OTC deficiency; low citrulline + normal/decreased orotic acid = CPS1 or NAGS deficiency; very high citrulline = ASS1 deficiency; detection of argininosuccinic acid = ASL deficiency; high arginine = ARG1 deficiency.
Quantification of urine orotic acid: Orotic acid is quantified by urine organic acid analysis (GC-MS) or a specific assay. Markedly elevated in OTC deficiency; normal or decreased in CPS1 and NAGS deficiency.
Enzyme activity measurement: CPS1 and OTC activity are measured in liver tissue (biopsy or surgery). ASL and ARG1 activity can be measured in red blood cells. NAGS activity is measured in liver tissue. Enzyme measurement is useful for diagnostic confirmation when no variant has been identified.
Molecular genetic testing: Targeted gene testing or UCD panel NGS is performed for the OTC gene (Xp11.4), CPS1 gene (2q35), NAGS gene (17q21.31), etc. Large deletions of OTC are confirmed by MLPA (multiplex ligation-dependent probe amplification). Identification of the gene variant is used for definitive diagnosis, family counseling, and prenatal diagnosis.
Specific diagnosis of NAGS deficiency: A dramatic decrease in blood ammonia after administration of carglumic acid strongly suggests NAGS deficiency. Other enzyme deficiencies do not show a response to carglumic acid.
Treatment of urea cycle disorders is divided into immediate treatment of acute hyperammonemia and long-term chronic management.
Emergency treatment of acute hyperammonemia: When blood ammonia is > 150 μmol/L or neurological symptoms are present, immediate emergency treatment is given. ① Complete discontinuation of protein intake (24-48 hours): removes the exogenous nitrogen load. ② High-calorie intravenous supply: glucose (8-10 mg/kg/min or more) and lipids (1-2 g/kg/day) are supplied intravenously to suppress catabolism and minimize ammonia production from endogenous protein breakdown. ③ Intravenous nitrogen scavengers: a combination preparation of sodium benzoate + sodium phenylacetate (Ammonul®) is given intravenously as a loading dose followed by a maintenance dose. Benzoic acid conjugates with glycine to form hippurate, and phenylacetic acid conjugates with glutamine to form phenylacetylglutamine, excreting nitrogen via the kidneys. ④ Intravenous arginine: in all UCD other than ARG1 deficiency, arginine becomes a conditionally essential amino acid, so arginine or citrulline is supplied intravenously in the acute phase. ⑤ Hemodialysis: when ammonia is > 400 μmol/L or central nervous system symptoms are progressing, rapid ammonia removal is performed with continuous renal replacement therapy (CRRT) or hemodialysis.
Specific treatment of NAGS deficiency: Oral carglumic acid (N-carbamylglutamate, Carbaglu®). Up to 100 mg/kg/day can be used in the acute phase, with a rapid ammonia-lowering effect. In NAGS deficiency it is also used as long-term maintenance treatment (usually 10-100 mg/kg/day).
Long-term chronic treatment: ① Low-protein diet: minimized within the range of age-specific protein requirements, with amino acid preparations supplemented under the guidance of a specialist metabolic dietitian to prevent essential amino acid deficiency. ② Oral nitrogen scavengers: glycerol phenylbutyrate (GPB, Ravicti®) or sodium phenylbutyrate (NaPBA, Buphenyl®) is given orally. GPB is lipid-based, requires a smaller dose than NaPBA, and has improved taste, so it is preferred. ③ Oral arginine/citrulline supplementation. ④ When metabolic decompensation is triggered by fever, infection, etc., emergency regimen: temporary discontinuation of protein intake, high-calorie supply (oral/tube feeding), increased nitrogen scavenger dose, and hospitalization if necessary.
Liver transplantation: The only curative treatment for urea cycle disorders. After liver transplantation, urea synthesis takes place in the normal liver, so blood ammonia normalizes and protein restriction is no longer needed. Both living-donor partial liver transplantation and deceased-donor liver transplantation are possible. Ideally, transplantation at a time when neurological damage is minimal (an early time, even in the severe neonatal form) is favorable for neurodevelopmental prognosis. Recovery from pre-existing neurological damage is limited even after transplantation.
The prognosis of urea cycle disorders is determined by the type of enzyme deficiency, residual enzyme activity, the severity and duration of the first hyperammonemic episode, and the timing of diagnosis and treatment initiation.
Prognosis of the severe neonatal form: Past data indicate a mortality of about 24-50% despite aggressive treatment in the complete-deficiency neonatal form of OTC deficiency or CPS1 deficiency. When blood ammonia > 500 μmol/L persists for 48 hours or longer, the proportion of survivors with severe neurodevelopmental disorders (intellectual disability, seizures, cerebral palsy) is high. Neonatal survival has now improved with early intensive treatment and prompt hemodialysis, but the neurological prognosis is still often poor.
Prognosis of the late-onset (mild) form: In patients who remain asymptomatic without metabolic stress until adulthood and are first diagnosed at an acute episode, normal function can be maintained after treatment if there was no neurological damage before the episode. However, the acute hyperammonemic encephalopathy episode itself can also cause neurological damage, so immediate treatment is important.
Prognosis after liver transplantation: After liver transplantation, blood ammonia normalizes, protein restriction becomes unnecessary, and quality of life improves greatly. If there was no neurological damage before transplantation, normal development is expected after transplantation. However, neurological damage that had already occurred before transplantation (intellectual disability, cerebral palsy) is difficult to recover even after transplantation. The transplant success rate is excellent, at 95% or higher.
Prognosis of female OTC carriers: Most can lead a normal life, but there is a risk of acute hyperammonemic encephalopathy, so monitoring during metabolic stress and establishing preventive protocols are important. In some, a low-protein diet and prophylactic nitrogen scavenger treatment are recommended. Pregnancy and delivery are particularly high-risk situations and should be managed in consultation with a metabolic specialist.
Prevention of urea cycle disorders consists of early neonatal diagnosis, avoidance of metabolic stress, and family genetic counseling.
Strengthening newborn screening: Because OTC, CPS1, and NAGS deficiency can be missed on current tandem MS/MS-based screening, clinical vigilance to measure blood ammonia immediately in a newborn with lethargy, vomiting, or hyperventilation is important. Positive screening findings (elevated/decreased citrulline, elevated arginine, etc.) should lead to immediate confirmatory testing. If there is a family history, molecular genetic confirmatory testing in the neonatal period is performed first.
Emergency regimen: All patients with urea cycle disorders and their caregivers should be familiar with the emergency regimen to apply when a situation that triggers metabolic decompensation, such as fever, decreased appetite, vomiting, or infection, occurs. The protocol includes temporary discontinuation of protein intake (up to 48 hours), administration of high-calorie oral supplements (mainly glucose), an increased nitrogen scavenger dose, and immediate visit to the emergency room if symptoms do not improve within 24 hours. Patients should always carry a Medical Alert card and be instructed to have emergency room staff measure blood ammonia immediately.
Diet and lifestyle management: An individualized low-protein diet is maintained routinely under the guidance of a specialist metabolic dietitian. High-protein foods (excessive intake of meat, legumes, and dairy products) are restricted, and fasting that promotes body protein breakdown is avoided. Prior consultation with a metabolic specialist is needed when planning long trips, air travel, or surgery. Female patients (especially OTC deficiency carriers) should establish a plan to prepare for the occurrence of hyperammonemia through multidisciplinary consultation with metabolic and obstetrics-gynecology specialists before pregnancy and delivery.
Genetic counseling: The mother and sisters of a patient with OTC deficiency should have their carrier status confirmed by molecular genetic testing, and prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT) should be considered in future pregnancies. Parents of patients with autosomal recessive UCD (CPS1, NAGS, etc.) are each carriers, and they are counseled about the 25% risk of disease in the next pregnancy.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Batshaw ML, Tuchman M, Summar M, Seminara J. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014;113(1-2):127-130. DOI: 10.1016/j.ymgme.2014.08.001. PMID: 25156442.
Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:1909-1963.
Wijburg FA, Nassogne MC. Disorders of the urea cycle and related enzymes. In: Saudubray JM et al., eds. Inborn Metabolic Diseases. 6th ed. Berlin: Springer; 2016:297-316.
Enns GM, Berry SA, Berry GT, et al. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282-2292. DOI: 10.1056/NEJMoa066596. PMID: 17538087.
Diez-Fernandez C, Häberle J. Targeting CPS1 as a therapeutic approach for urea cycle disorder. Expert Opin Ther Targets. 2017;21(11):1077-1086. DOI: 10.1080/14728222.2017.1370688. PMID: 28857675.
Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders. Pediatr Clin North Am. 2018;65(2):231-246. DOI: 10.1016/j.pcl.2017.11.004. PMID: 29502910.
Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35(5):777-785. DOI: 10.1007/s10545-012-9461-4. PMID: 22307250.
Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007;30(6):865-879. DOI: 10.1007/s10545-007-0709-5. PMID: 18027194.
Lee B, Diaz GA, Rhead W, et al. Blood ammonia and glutamine as pharmacodynamic markers for intermediate-acting glycerol phenylbutyrate in patients with urea cycle disorders. Mol Genet Metab. 2015;114(3):382-389. DOI: 10.1016/j.ymgme.2014.11.007. PMID: 25535082.